Integrative Management of Opioid Use Disorder: Bridging Evidence-Based Pharmacotherapy, Harm Reduction, and Multidisciplinary Spinal Care

Welcome to our comprehensive clinical guide on understanding, mitigating, and managing opioid use disorder (OUD). I am Dr. Alex Jimenez, and my practice is centered on an integrative, whole-person paradigm of restorative health. As a Doctor of Chiropractic (DC), Advanced Practice Registered Nurse (APRN), board-certified Family Nurse Practitioner (FNP-BC), and Certified Functional Medicine Practitioner (CFMP, IFMCP), I view substance use disorders and chronic pain through a biomechanical, neurochemical, and physiological lens.

At Injury Medical Clinic PA in El Paso, Texas, our clinical model combines advanced chiropractic rehabilitation, functional medicine, and comprehensive internal medicine oversight under our Medical Director, Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine, NPI #1164426749, Texas MD License #J2933). Together, we treat individuals caught in the cycle of acute personal injury, intractable mechanical dysfunction, and chemical dependency.

This clinical post examines the diagnostic framework of OUD, modern medications for opioid use disorder (MOUD), harm reduction, and the role of conservative chiropractic interventions in down-regulating central sensitization, alleviating severe secondary musculoskeletal comorbidities, and reducing overall reliance on opioids.

The Intersecting Crises of Chronic Pain and Opioid Use Disorder

Over 100,000 Americans die annually from drug overdoses, with opioids driving approximately 80% of these fatalities (Ahmad et al., 2023). While synthetic opioids like illicitly manufactured fentanyl and toxic adulterants like xylazine dominate acute mortality patterns, a high percentage of patients with OUD initially encounter opioids following an acute musculoskeletal trauma, motor vehicle collision, or persistent spine-related pain syndrome.

+-----------------------------------------------------------------------------------+
|               The Reciprocal Pain-Addiction-Dysfunction Cycle                     |
+-----------------------------------------------------------------------------------+
|                                                                                   |
|   +--------------------------+               +--------------------------------+   |
|   |   Musculoskeletal Injury | ------------> | Persistent Mechanical Pain     |   |
|   |   & Spinal Subluxation   |               | & Soft-Tissue Inflammation     |   |
|   +--------------------------+               +--------------------------------+   |
|                ^                                             |                    |
|                |                                             v                    |
|   +--------------------------+               +--------------------------------+   |
|   | Muscle Wasting, Spasm &  |               | Long-Term Opioid Exposure      |   |
|   | Altered Postural Tone    |               | (Receptor Desensitization)     |   |
|   +--------------------------+               +--------------------------------+   |
|                ^                                             |                    |
|                |                                             v                    |
|   +--------------------------+               +--------------------------------+   |
|   | Opioid-Induced           | <------------ | Central Sensitization &        |   |
|   | Hyperalgesia (OIH)       |               | Autonomic Dysregulation        |   |
|   +--------------------------+               +--------------------------------+   |
|                                                                                   |
+-----------------------------------------------------------------------------------+

When tissue injury transforms into chronic pain, prolonged opioid use alters central pain pathways. Patients encounter opioid-induced hyperalgesia (OIH), a neurobiological phenomenon characterized by paradoxical pain sensitization triggered by the very agent prescribed for analgesia. In our El Paso clinical observations, breaking this loop demands non-pharmacological interventions that address the structural and biomechanical sources of nociception while supporting medical stabilization.

Diagnostic Criteria and Severity Stratification (DSM-5-TR)

Accurate identification remains fundamental to early intervention. Per the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), OUD is defined as a problematic pattern of opioid use leading to clinically significant impairment or distress, manifested by at least two of the following 11 criteria over12 monthsd (American Psychiatric Association, 2022):

1. Larger Amounts/Longer Duration: Consuming opioids in greater quantities or for longer periods than intended.

2. Persistent Desire/Failed Control: Chronic unsuccessful efforts to cut down or regulate intake.

3. Time Investment: Disproportionate time spent obtaining, using, or recovering from opioid effects.

4. Craving: Intense, intrusive urges to use opioids driven by conditioned neurochemical pathways.

5. Role Failure: Recurrent use that fails to meet obligations at work, school, or home.

6. Social/Interpersonal Problems: Continued use despite persistent interpersonal strain caused or exacerbated by the substance.

7. Neglect of Activities: Forfeiting essential recreational, occupational, or social pursuits.

8. Hazardous Use: Recurrent administration in physically precarious environments (e.g., driving or operating machinery while intoxicated).

9. Physical/Psychological Harm: Continued consumption despite knowing that a physical or psychological problem is caused or intensified by the drug.

10. Tolerance: A physiological need for higher doses to achieve baseline effects, or a diminished response to identical amounts.

11. Withdrawal: Characteristic withdrawal syndrome upon cessation, or consumption of opioids to abort withdrawal sickness.

Severity Stratification:

• Mild: Presence of 2 to 3 symptoms.

• Moderate: Presence of 4 to 5 symptoms.

• Severe: Presence of 6 or more symptoms.

Clinicians must note whether the patient is In Early Remission (3-12 months without meeting criteria, excluding craving), In Sustained Remission (12+ months), or On Maintenance Therapy (e.g., buprenorphine or methadone).

Pharmacological Interventions: Medications for Opioid Use Disorder (MOUD)

MOUD remains the foundation of outpatient mortality reduction and physiological stabilization (National Academies of Sciences, Engineering, and Medicine, 2019). The three FDA-approved agents provide unique mechanisms:

Addressing Fentanyl Kinetics and Precipitated Withdrawal

Lipophilic synthetic opioids like fentanyl distribute deeply into adipose stores, extending clearance times and predisposing individuals to severe precipitated withdrawal when initiating partial agonists. Standard initiation typically requires objective confirmation of moderate withdrawal using the Clinical Opiate Withdrawal Scale (COWS), scoring resting pulse, piloerection, tremor, diaphoresis, and pupillary dilation.

To bypass this barrier without inducing distress, clinical practice increasingly relies on microdosing protocols (the Bernese Method). Very low buprenorphine doses (e.g., 0.25 mg to 0.5 mg) are introduced while the full agonist continues, then titrated upward over 7 to 10 days to occupy receptors systematically without precipitating an autonomic crisis.

Public Health Paradigms: Harm Reduction and Motivational Interviewing

Harm reduction strategies acknowledge patient dignity and mitigate mortality:

• Intranasal Naloxone Distribution: Community deployment of high-affinity opioid antagonists reverses life-threatening respiratory depression.

• Syringe Service Programs (SSPs): Prevent blood-borne pathogen transmissions (HIV, Hepatitis C) and soft-tissue bacterial infections like endocarditis and abscesses (Des Jarlais et al., 2009).

• Test Strip Implementation: Detection of illicit fentanyl and xylazine adulteration prevents accidental overdose. Because test strips follow an inverse pattern (one red line indicates a positive result; two lines indicate a negative result), patient education on the “chocolate chip cookie effect” (heterogeneous drug distribution) is vital.

• Wound Management: Xylazine induces severe vasoconstrictive necrosis that manifests distal to injection sites, necessitating rapid debridement, sterile barrier care, and systemic evaluation.

       [Precontemplation]  --->  [Contemplation]  --->  [Preparation]
               ^                                               |
               |                                               v
          [Recurrence]     <---  [Maintenance]   <---      [Action]

Motivational Interviewing via OARS

Communication within our El Paso clinic uses the Transtheoretical Model to explore patient ambivalence (Prochaska & DiClemente, 1983):

• O – Open-Ended Inquiries: “What role does your medication play in managing your lower back symptoms?”

• A – Affirmations: “Acknowledging how pain affects your daily routine shows a strong commitment to recovery.”

• R – Reflective Listening: Mirroring emotional distress to validate patient vulnerability without defensiveness.

• S – Summarization: Consolidating insights, exploring discrepancies between current substance intake and life values, and utilizing readiness/confidence rulers.

The Biomechanical Axis: How Chiropractic Care Reduces Opioid Reliance

While pharmacological stabilization treats neurochemical dependence, it does not resolve the structural pathology driving nociceptive input. Integrative chiropractic care functions as a non-pharmacological alternative that relieves pain at the biomechanical level, reducing the physiological drive to escalate opioid dosages.

1. Neurophysiological Modulation of Central Nociceptive Input

Chronic musculoskeletal trauma—such as whiplash-associated disorders, facet syndrome, or lumbar disc herniations—creates aberrant afferent signaling. Subluxated or restricted articular joints bombard the spinal cord’s dorsal horn with repetitive, high-frequency nociceptive traffic.

+-----------------------------------------------------------------------------------+
|                        Spinal Gate Control Modulation                             |
+-----------------------------------------------------------------------------------+
|                                                                                   |
|  High-Velocity, Low-Amplitude (HVLA) Adjustment                                  |
|         |                                                                         |
|         v                                                                         |
|  Rapid Stretch of Paraspinal Muscle Spindles & Joint Mechanoreceptors (Type I/II) |
|         |                                                                         |
|         v                                                                         |
|  Afferent Volley through Large-Diameter A-beta Nerve Fibers                      |
|         |                                                                         |
|         v                                                                         |
|  Inhibition of Nociceptive Transmission (A-delta & C Fibers) at the Substantia    |
|  Gelatinosa (Dorsal Horn Gate Mechanism)                                          |
|         |                                                                         |
|         v                                                                         |
|  Down-Regulation of Substance P, CGRP, and Central Hyperexcitability             |
|                                                                                   |
+-----------------------------------------------------------------------------------+

High-Velocity, Low-Amplitude (HVLA) chiropractic manipulation delivers a mechanical stimulus to articular mechanoreceptors (Types I and II) and paraspinal muscle spindles. This rapid input travels through large-diameter, myelinated A-beta sensory fibers, enters the dorsal horn, and activates inhibitory interneurons within the substantia gelatinosa.

Per the classic Gate Control Theory of Melzack and Wall, this process inhibits presynaptic transmission of slow, unmyelinated C fibers and lightly myelinated A-delta fibers, halting the ascending nociceptive barrage before it reaches the thalamus and sensory cortex. By interrupting this afferent stream, spinal manipulation decreases localized pain signaling and calms central sensitization.

2. Autonomic Tone Normalization and Neuroendocrine Balance

Opioid dependency and acute withdrawal cause sympathetic hyperarousal. Autonomic dysfunction manifests as elevated resting heart rates, hypertension, muscle splinting, insomnia, and gastrointestinal distress.

Spinal adjustments in the upper cervical and lumbosacral regions influence autonomic nervous system tone. Biomechanical mobilization of spinal segments can dampen sustained sympathetic outflow (fight-or-flight responses) while encouraging parasympathetic modulation. This shift helps soothe the neuroendocrine stress response, blunting cortisol and catecholamine spikes that aggravate chronic pain and worsen withdrawal symptoms.

3. Reversing Opioid-Induced Hyperalgesia (OIH) via Structural Restoration

Patients on long-term opioid therapy often experience a lower pain threshold due to receptor desensitization and neuroinflammatory signaling in the spinal cord. Minor mechanical misalignments then register as severe pain.

Conservative spinal therapy restores physiologic joint kinematics, relieves intra-articular pressure, enhances disc hydration through non-surgical spinal decompression, and reduces mechanical strain on adjacent neural pathways. Correcting these structural deficits lowers baseline nociceptive input, counteracting the effects of OIH and allowing patients to taper or stabilize their opioid dosages under medical supervision.

Treating Musculoskeletal Comorbidities Associated with OUD

Opioid Use Disorder triggers secondary physical and functional complications that impair physical rehabilitation if left unaddressed.

+----------------------------------------------------------------------------------+
|                   Musculoskeletal Comorbidities of OUD                           |
+----------------------------------------------------------------------------------+
|                                                                                  |
|   Sedentary Sedation               Chronic Systemic        Postural Collapse     |
|   & Prolonged Recumbency           Inflammation & Wasting  & Muscle Splinting    |
|            |                                |                       |            |
|            v                                v                       v            |
|   +------------------+             +-----------------+     +-----------------+   |
|   | Joint Capsule    |             | Sarcopenia &    |     | Pelvic/Cervical |   |
|   | Contractures &   |             | Ligamentous     |     | Crossed         |   |
|   | Adhesions        |             | Laxity          |     | Syndromes       |   |
|   +------------------+             +-----------------+     +-----------------+   |
|            \                                |                      /             |
|             \                               |                     /              |
|              +------------------------------+--------------------+               |
|                                             |                                    |
|                                             v                                    |
|                      Targeted Integrative Chiropractic Care:                     |
|                      * Passive/Active Functional Decompression                   |
|                      * Soft-Tissue Mobilization & Myofascial Release             |
|                      * Core-Stabilizing Rehabilitative Kinesiology               |
|                                                                                  |
+----------------------------------------------------------------------------------+

Prolonged Immobility and Kinetic Chain Collapse

Chronic sedation or periods of intoxication frequently lead to sustained, unphysiological postures. Patients can develop severe compression neuropathies, postural deformities, myofascial trigger points, and reciprocal muscle inhibition.

Our clinical assessments often reveal pronounced Lower and Upper Crossed Syndromes—deep cervical flexor weakness, anterior head translation, hyperkyphosis, lumbar hyperlordosis, and psoas contractures.

Chiropractic rehabilitation addresses these structural imbalances through:

• Targeted Spinal Adjustments: Restore segment-level arthrokinematics and joint mobility throughout the kinetic chain.

• Myofascial Release Techniques: Break up dense fibrotic adhesions, restore fascial glide, and mitigate painful ischemic contractures.

• Active Rehabilitation: Retrains the deep intrinsic spinal stabilizers (transversus abdominis, multifidus, and deep neck flexors) to re-establish postural equilibrium and functional endurance.

Systemic Inflammation and Functional Medicine Co-Management

Opioid dependence is frequently accompanied by gut dysbiosis, systemic inflammation, and nutritional deficiencies that delay soft tissue healing and heighten systemic pain perception.

Working alongside Dr. Maria Guadalupe Cardenas, our clinical evaluations screen for infectious markers, systemic liver status, metabolic dysregulation, and gut-barrier integrity. Combining medical oversight, targeted nutritional support, anti-inflammatory dietary strategies, and conservative musculoskeletal rehabilitation provides a coordinated, whole-person foundation for sustained recovery.

References

• Ahmad, F. B., Cisewski, J. A., Rossen, L. M., & Sutton, P. (2023). Provisional drug overdose death counts. National Center for Health Statistics.

• American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). American Psychiatric Association.

• Centers for Disease Control and Prevention. (2023). Fentanyl facts. U.S. Department of Health and Human Services.

• Des Jarlais, D. C., Marmor, M., Paone, D., Titus, S., Shi, Q., Perlis, T., & Friedman, S. R. (2009). HIV incidence among injecting drug users in New York City, 1990 to 2002: Use of serologic test algorithm to assess expansion of HIV prevention services. American Journal of Public Health, 99(S1), S35-S40.

• Felitti, V. J., Anda, R. F., Nordenberg, D., Williamson, D. F., Spitz, A. M., Edwards, V., Koss, M. P., & Marks, J. S. (1998). Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults: The Adverse Childhood Experiences (ACE) Study. American Journal of Preventive Medicine, 14(4), 245-258.

• Jimenez, A. (n.d.). Injury Medical Clinic & Functional Wellness. Wellness Doctor Rx.

• Jimenez, A. (n.d.). Alex Jimenez, DC, APRN, FNP-BC – Professional Profile. LinkedIn.

• Meinhofer, A., Witman, A., & Brolin, M. (2021). Buprenorphine-methadone ratio and opioid overdose mortality. The American Journal of Managed Care, 27(7), 282-287.

• Miller, W. R., & Rollnick, S. (2013). Motivational interviewing: Helping people change (3rd ed.). The Guilford Press.

• National Academies of Sciences, Engineering, and Medicine. (2019). Medications for opioid use disorder save lives. The National Academies Press.

• Prochaska, J. O., & DiClemente, C. C. (1983). Stages and processes of self-change of smoking: Toward an integrative model of change. Journal of Consulting and Clinical Psychology, 51(3), 390-395.

• Substance Abuse and Mental Health Services Administration. (2022). Key substance use and mental health indicators in the United States: Results from the 2021 National Survey on Drug Use and Health. Center for Behavioral Health Statistics and Quality.

opioid use disorder, OUD, integrative chiropractic care, Dr. Alex Jimenez, Dr. Maria Cardenas, El Paso chiropractor, musculoskeletal pain, opioid-induced hyperalgesia, spinal manipulation, gate control theory, buprenorphine, Suboxone, methadone, naltrexone, MOUD, harm reduction, naloxone, syringe service programs, xylazine, fentanyl test strips, Bernese method, microdosing, motivational interviewing, OARS, stages of change, personal injury rehabilitation, functional medicine, chronic pain management, spinal adjustments, biomechanical rehabilitation, substance use disorder treatment, Injury Medical Clinic PA